• Digital money is replacing physical cash, and FEXD is developing mobile transaction platforms and services that are helping implement the coming changes in the fintech market
• FEXD plans to acquire and merge with companies that include country-based fintech pioneers with global scalability, fintech service providers, companies with large customer bases, and more
• The company is helping ensure humanity has a path forward from archaic and restrictive cash systems – reducing poverty, improving the lives of the unbanked, providing critical financial options for migrant workers, connecting families and communities, empowering charities and women, and educating underprivileged children

With plans to offer a diverse portfolio of fintech-related products and services for consumers and businesses in the United States, South Asia, East Asia, Africa, Europe, and Latin America, Fintech Ecosystem Development (NASDAQ: FEXD) continues to move forward in the service of underserved and overlooked markets within the global financial ecosystem. The FEXD management team has extensive experience in developing and managing financial service platforms and applications, primarily in the mobile money sector, driving the move to a cashless society.

Digital money is replacing physical cash, with consumers able to buy products and services anywhere in the world and make payments across borders. FEXD is developing mobile transaction platforms and services that are helping implement the coming changes – especially in underserved and overlooked markets like rural areas and Asia, the Middle East, Africa, and Latin America.

FEXD supports the United Nations’ Sustainable Development Goal to reduce cross-border transaction costs from 7 percent to 3 percent. The company’s use of advanced technology is lowering fintech costs and international fees for cross-border transactions.

The company’s growth strategy includes seeking the acquisition and merging of high growth fintech primarily operating in South Asia. The target companies that FEXD plans to acquire and merge with will help the company grow to $1 billion and more in annual revenues as a part of the global fintech ecosystem it is developing. The companies that FEXD plans to acquire/merge with will exhibit the following characteristics:

• Country-based fintech pioneers with the global scalability
• Fintech service providers that will benefit from integrating more advanced technologies
• Fintech companies with a large existing customer base
• A shared interest in making an impact by bringing mobile transaction services to under-served markets
• Growth-oriented management teams
• Attractive valuation

FEXD is committed to supporting the fintech and digital money processes in developing countries and cultures. Using its keen understanding of market needs in regions worldwide, the company is helping ensure humanity has a path forward from an unhygienic cash system – reducing poverty, improving the lives of the unbanked, offering securing and savings options for migrant workers, connecting families and communities, empowering charities and women, and educating underprivileged children.

According to McKinsey research, there are four major trends driving the growth of digital payments worldwide, especially in emerging markets like Africa and Southeast Asia, where low banking penetration allows payment providers to capture untapped potential and reach underserved populations. The first trend, the pandemic, accelerated the contactless digital payments frontier. Second, e-commerce continues to grow and evolve, with global volumes expected to increase by 12 to 15 percent annually by 2025. Third, the government is pushing for cashless payments to facilitate interoperability, plug tax leakages, and ensure effective aid distribution. Lastly, McKinsey points out investor appetites for digital payments, leading to a proliferation of payments-focused fintechs (https://ibn.fm/oOGOX).

Many areas of the world have severely underserved financial service markets. Millions of people require faster and cheaper ways to transfer money directly across borders to fund business transactions and provide support. Mobile money platforms provide a solution to the billions of people who own a cell phone but do not have access to a bank. FEXD services allow people in other countries to access USD online accounts that are FDIC insured.

For more information, visit the company’s website at www.FintechEcoSys.com.

NOTE TO INVESTORS: The latest news and updates relating to FEXD are available in the company’s newsroom at https://ibn.fm/FEXD

• Lexaria recently completed its animal study HOR-A22-1 showing its patented DehydraTECH(TM) technology dramatically enhanced the oral delivery of estradiol, a type of estrogen hormone
• The use of DehydraTECH resulted in ~900% higher peak concentration of estradiol in the bloodstream compared to the control, as well as a 2,000% increase in the levels of estrone
• Estrone is a type of estrogen that can be reversibly made from estradiol in certain tissues within the female body
• The study HOR-A22-1 also revealed that DehydraTECH resulted in 1,500% and 12,500% higher exposure to estradiol and estrone over time, respectively, compared to the control
• Lexaria also announced the closing of a public offering that raised approximately $2 million in gross proceeds

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported that it had completed its animal study HOR-A22-1, which showed that the company’s patented DehydraTECH(TM) technology platform significantly enhanced the oral delivery of the estrogen hormone estradiol (https://ibn.fm/ywP2y).

Performed in 20 female Sprague-Dawley rats, the pharmacokinetic study compared a DehydraTECH-estradiol formulation to a generic estradiol composition, both containing 10 mg/kg of estradiol, to evaluate the ability of DehydraTECH to enhance the delivery properties of the orally administered hormone. Once dosing was completed, blood was collected up to 48 hours post-dosing, with the concentration of estradiol and estrone determined thereafter.

Estradiol is a major female sex hormone and the most common form of estrogen in women of childbearing age. It is normally made in the ovaries (although it is also manufactured in the testicles in men, albeit in small quantities) but can be administered as an oral tablet, topical gel or patch, cream, or injection to reduce the symptoms of menopause and protect bone health. It is also found in birth control products. Put simply, estradiol is an important element of therapeutic products in the women’s health sector. On the other hand, Estrone is the only type of estrogen that females continue to manufacture after menopause. It is primarily made in the adrenal glands (in both males and females), although it is also reversibly manufactured from estradiol in tissues found in the mammary gland, uterus, and liver, a factor that informed the study’s measurement of estrone levels.

The study found that the DehydraTECH-estradiol composition resulted in a maximum concentration in the bloodstream (“Cmax”) of 5.65 ng/mL, which was approximately 900% higher than the control formulation’s Cmax (0.63 ng/mL). Additionally, the use of the DehydraTECH-formulation resulted in a 2,000% increase in the levels of the estrone metabolite, also measured using the Cmax parameter: DehydraTECH-estradiol resulted in a Cmax of 6.49 ng/mL compared to the control’s 0.302 ng/mL.

Additionally, the study evaluated the area under the curve (“AUC”), a parameter that gave insight into the total delivery of estradiol over time as well as the extent of exposure to estrone. The AUC was 3.9 hr.ng/mL for estradiol and 32.6 hr.ng/mL for estrone when the DehydraTECH-processed composition was used. In comparison, the AUC after administering the control was non-detectable for both estradiol and estrone, as it was below 0.25 ng/mL, the lower limit of quantitation of the assay. This means the AUC findings were 1,500% and 12,500% greater than the control for estradiol and estrone, respectively.

Considered an additional step that is readily incorporated into the formulation and manufacturing process of existing or new orally ingestible and topical products, DehydraTECH has been shown to improve the proportion of the drug delivered into the bloodstream (bioavailability) and the absorption of drugs into the brain tissue. Among the drugs that can benefit from these improvements is oral estradiol, which has minimal bioavailability (2% to 10%) due to gut and liver metabolism (https://ibn.fm/kbdx1). This, according to Lexaria, often necessitates high dosages to achieve the desired beneficial effect; but this can, in turn, lead to unwanted side effects. Thus, incorporating DehydraTECH into the manufacturing process of oral estradiol and potentially other human hormone therapies may enhance their oral delivery.

The animal study HOR-A22-1, which is part of Lexaria’s efforts to pursue multiple paths to success by investigating several large market opportunities, represents a foray into the hormone replacement market estimated to grow from $31.06 billion in 2019 to an estimated $46.50 billion by 2027, a 5.1% CAGR (https://ibn.fm/PnAIK).

Meanwhile, Lexaria also announced the closing of its public offering of 2,106,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock. The offering generated approximately $2.0 million in gross proceeds.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Smart organizations are encouraged to meet certain standards and regulations to protect data against cybersecurity threats
• With more than 15 billion user credentials scattered across the dark web, the threat is real
• CEO notes that compliance is an important driver for security, and organizations should never view it as a mere technical nuisance

Complying with security requirements should be about more than just ticking off mandatory checkboxes, says CISO Global (NASDAQ: CISO) CEO David Jemmett (https://ibn.fm/dDN38). CISO Global, formerly Cerberus Cyber Sentinel Corp., works closely with companies to provide essential protection, and Jemmett is a recognized expert in the field of cybersecurity.

“Today, all organizations are required or encouraged to meet certain standards and regulations to protect their data against cybersecurity threats,” writes Jemmett in a guest essay for The Last Watchdog. “The regulations vary across countries and industries, but they are designed to protect customers from the threat of posed data breaches.”

That threat is real, notes Jemmett, citing estimates that currently more than 15 billion user credentials are scattered across the dark web. “The importance of compliance is clear to see,” he writes. “In spite of this, many organizations today still see compliance as a nuisance, rather than a business enabler. All too often, organizations will analyze compliance requirements and harden their systems and practices to meet them, without really thinking about their importance to the business. Instead, they will tick the mandatory checkboxes, even if security measures haven’t been enacted, and file the record away as quickly as possible.”

This approach is dangerous, explains Jemmett, noting that single “point-in-time” compliance doesn’t cut it in today’s threat landscape. “Compliance is no longer a ‘set and forget’ security framework,” he continues. “To keep up to speed in today’s evolving threat landscape, compliance is a process that must be maintained continuously.”

In his essay, Jemmett offers several tips to help companies implement an effective cybersecurity compliance strategy, providing timely, relevant protection against current as well as new and emerging threats. These suggestions include staying up-to-date with the evolving and growing attack surface, taking a risk-based approach and remembering that cybersecurity is a culture, not a product. “Compliance is an important driver for security, and organizations should never view it as a mere technical nuisance. Cybersecurity is a critical business enabler today, and those that get it right will excel. Those that get it wrong, and do not prioritize their defenses, could stand to lose everything,” Jemmett concluded.

CISO Global is gaining recognition as a leading provider of global cybersecurity and compliance as it rapidly expands by acquiring world-class cybersecurity, secured-managed services and compliance companies. These acquisitions bring top-tier talent to the CISO table, enabling the company to utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations, mitigating continuing and emerging security threats and compliance obligations.

For more information, visit the company’s website at www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

• Biotechnology innovator BiondVax Pharmaceuticals is dedicated to developing nanosized antibody (NanoAb) treatment
• BiondVax is also leveraging its team experience in preclinical stage to Phase 3 clinical trial product development to generate new revenues by offering cGMP contract development and manufacturing organization (“CDMO”) services
• The company recently exhibited its CDMO expertise as well as its NanoAb development pipeline at the 21st annual Biomed Israel conference, which drew over 6,000 attendees from a wide variety of international life sciences disciplines
• BiondVax’s NanoAb drug candidate pipeline has expanded focus on immune system cytokine targets for treating psoriasis and psoriatic arthritis

Israel-based biotechnology company BiondVax Pharmaceuticals (NASDAQ: BVXV) is building on positive preclinical data regarding its innovative inhaled anti-SARS-CoV-2 nanosized antibody (NanoAb) product with plans to develop further NanoAbs targeting immune system cytokines while the company expands its frontiers by beginning to offer contract development and manufacturing organization (“CDMO”) services.

BiondVax showcased its CDMO services and expertise at the premier conference for international Life Science and HealthTech industries earlier this month in Israel. The 21st annual Biomed Israel drew more than 6,000 industry leaders, scientists, engineers, physicians, and investors from over 45 countries, providing BiondVax a worldwide stage for exhibiting its potential blockbuster products and state-of-the-art assets and services.

“Senior executives and delegations from multinationals, big pharma, medical devices, tech giants and international investors in the health industry come to Israel each May to ‘shop for’ innovation in the field, in search of creative solutions, products and technologies, and the next big thing,” Biomed Israel Co-chairwoman Ruti Alon stated in a news release about the event (https://ibn.fm/jWiGl).

BiondVax has gained significant expertise in developing and producing current good manufacturing practice (“cGMP”) compliant drug candidates, working from preclinical stage to Phase 3 clinical trials. Making its cGMP manufacturing facility available for the development of other companies’ products helps to advance the potential of improving medical therapies and responding to unmet medical needs.

The company’s CDMO services include aseptic filling, upstream and downstream process development, as well as analytical model development. BiondVax is contracting its suite of boutique end-to-end services (https://ibn.fm/ArbDX) to large pharmaceutical and biotech companies, alternative protein food tech companies, and smaller development-stage companies in general.

Offering CDMO services “allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,” CEO Amir Reichman stated in a year-end letter to shareholders (https://ibn.fm/FRmQg).

“The team already knows how to work together. The team has experience with running pre-clinical trials, clinical trials, chemistry, manufacturing and controls [CMC], quality assistance — everything works; it’s an oiled machine. Also the capacity and the capabilities are there,” Reichman said in a March interview with Digital Niche Agency that addressed BiondVax’s efforts to strengthen its value for its shareholders (https://ibn.fm/IAcxF).

A recent statement on the company’s quarterly financial results noted that the company has begun R&D activities for the innovative NanoAb platform targeting immune system cytokines. The drug candidate development process will focus on cytokines such as IL-17 for their potential in treating psoriasis and psoriatic arthritis, both large market disorders with large unmet medical needs.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• MULN received an order for one thousand class 3 trucks from its dealer partner, Randy Marion Automotive
• The company is excited about entering the next phase of its commercial launch with the Mullen THREE
• Mullen inked a $15 million vehicle purchase agreement with the MGT Lease Company for 250 class 3 cab chassis EV trucks

On the heels of several purchase agreements and orders, Mullen Automotive (NASDAQ: MULN) is experiencing impressive momentum as it continues to focus on growing in the electric vehicle space. Most recently, the company received a 1,000-unit purchase order (https://ibn.fm/2tLyU) and announced a $15.7 million vehicle purchase order with a lease company, both for its Mullen THREE class 3 truck (https://ibn.fm/y31v4).

The order for one thousand class 3 trucks came from Mullen’s dealer partner, Randy Marion Automotive, which earlier this month received the first class 3 demonstration vehicle for customer test drives and demonstrations. “Based on the tremendous interest we received on the Mullen class 3 truck, we placed our 1,000-vehicle order,” said Brad Sigmon, the fleet general manager and vice president of Randy Marion Automotive fleet operations. “We have a lineup of our customers waiting to pilot this truck including Duke Energy, Lowes and UNC-Charlotte.”

Mullen has announced that the class 3 truck will be priced at $68,500 and includes an estimated 130-mile range along with a 5,800-pound payload and capability of carrying a 14-foot box with more than 1,000 cubic feet of cargo capacity.

Mullen chief commercial officer John Schwegman noted that the company is excited about entering the next phase of its commercial launch with the Mullen THREE, which he identified as “the customers, piloting, testing and evaluation stage. Demand has been strong since we introduced this product and the aggressive price point. We are excited to get customers behind the wheel of our class 3 product.”

In addition, Mullen signed a vehicle purchase agreement, valued at more than $15.7 million, with MGT Lease Company, for 250 class 3 cab chassis EV trucks. According to the agreement, Mullen will begin delivering the first of the trucks in August 2023, with all vehicles being delivered by the end of the year.

A growing commercial vehicle sales and leasing company based in North Carolina, MGT is focused on a customer base that is looking for last-mile delivery solutions, such as package delivery and retail, along with vocations such as plumbing and electrical. MGT has ordered the all-electric class 3 EV cab chassis trucks for addition to its short- and long-term fleet leasing portfolio. MGT has worked with Mullen before; the company initially purchased EV cargo vans earlier this year. “We are very happy with the Mullen EV cargo van and have received great customer feedback and are now looking forward to expanding into Mullen’s commercial class 3 truck,” said Greg Striker, a partner at MGT Lease Co.

Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana.

For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

Gene Therapy’s Transformative Potential Highlighted in Inspiring Patient Video Interview with Genprex’s (NASDAQ: GNPX) REQORSA on Benzinga.

Click Here for the full article

The interview showcases the real-life experience of a patient participating in a clinical trial utilizing Genprex’s innovative gene therapy drug candidate, REQORSA, shedding light on the significant impact it could potentially have in advancing the treatment of non-small cell lung cancer.

The featured video highlights the compelling story of Jacqueline Marino, a participant in the Phase 1 segment of Genprex’s Phase 1/2 Acclaim-1 clinical trial. Marino, diagnosed with non-small cell lung cancer (“NSCLC”), offers an inspiring account of her experience with REQORSA(R) Immunogene Therapy, Genprex’s flagship drug candidate, in combination with Tagrisso(R).

Marino’s narrative centers on the significant positive impact REQORSA has had on her life. Her treating physician observed that her lung cancer lesions remained stable, devoid of any signs of growth. This stability, combined with an extended period of Progression-Free Survival (“PFS”), has led to an enhanced quality of life and invaluable additional time for Marino.

REQORSA Immunogene Therapy represents a potentially groundbreaking experimental drug that harnesses the power of genetic medicine to combat NSCLC. The Acclaim-1 trial evaluates the safety and efficacy of combining REQORSA with Tagrisso in patients with advanced EGFR mutant NSCLC who have experienced disease progression after previous treatments.

During the Phase 1 portion of the clinical trial, the primary emphasis is on evaluating the safety of the treatment. However, the findings also have revealed promising efficacy results. One patient previously treated with standard of care therapies such as osimertinib had a partial remission (“PR”) by investigator evaluation and treatment is ongoing after 16 cycles, which is approximately 10.5 months. Another patient previously treated with osimertinib, has stable disease and treatment is ongoing after 14 cycles, or approximately 9 months. The extended and ongoing progression free survival (“PFS”) of each of these patients is significantly greater than the median PFS observed from treatment with osimertinib alone in this treatment setting in several prior clinical trials and is consistent with long-term PFS seen in prior clinical trials of REQORSA. These findings underscore the potential of REQORSA in reshaping the landscape of non-small cell lung cancer.

The release of the patient video interview on Benzinga coincides with the successful completion of the Phase 1 portion of the Acclaim-1 clinical trial. The compelling patient story, combined with the Safety Review Committee’s approval to proceed with the Phase 2 expansion segment, signify significant milestones in the development of REQORSA Immunogene Therapy.

While REQORSA is currently in early-stage clinical studies and will require successful large scale studies prior to regulatory approval and commercial availability, the patient video interview on Benzinga provides a captivating glimpse into the transformative potential of gene therapy. Marino’s journey serves as an inspirational testament to the promise of REQORSA in addressing the critical needs of NSCLC patients.

To watch Jacqueline Marino’s powerful story and delve deeper into REQORSA Immunogene Therapy, visit the featured video on Benzinga.

*It is important to note that REQORSA is an investigational drug and has not received approval from the U.S. Food and Drug Administration or any other regulatory authority. The experiences shared in the video are unique to Jacqueline Marino and may not be representative of the outcomes experienced by other patients undergoing REQORSA treatment.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• In 2019, Quebec became the first Canadian province to mandate the inclusion of renewable natural gas (“RNG”) in natural gas distribution; other provinces have followed suit
• EverGen Infrastructure as a renewable energy leader in Canada, specializing in RNG with operations in B.C., Alberta, and Ontario
• EverGen has agreements with provincial governments and businesses to bat for organic feedstock and supply agreements with major Canadian utilities, including FortisBC, to include RNG in their pipelines

Renewable energy forms a cornerstone of environmental sustainability, with nations worldwide realizing the immense potential of harnessing naturally occurring energy sources. One such pivotal renewable source is biogas, produced by the anaerobic digestion of organic waste from landfills, agricultural waste, and wastewater from treatment facilities. Biogas is further processed into RNG (renewable natural gas), a carbon-negative product that is essentially indistinguishable from conventional natural gas collected from drilled wells. Canada is fast becoming a global leader in this arena, as is EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), capitalizing on its unique attributes and comprehensive sustainability strategies that outshine many of its international counterparts.

A key advantage of Canada’s biogas push compared to other countries is its vastness and diverse landscapes. In 2019, Quebec became the first province to mandate the inclusion of RNG in natural gas distribution. According to Canada Energy Regulator,18 new RNG projects built after 2021 will increase Canada’s RNG capacity from 7.2 petajoules (“PJ”) in 2021 to 17.1 PJ in 2025. With expansive agricultural lands and numerous livestock operations, the country possesses an abundant and continuous supply of raw materials needed for biogas production. Notably, agricultural waste, a primary input, is available in substantial quantities, thereby creating a mutually beneficial relationship between agriculture and renewable energy sectors.

Secondly, the Canadian government’s strong commitment to environmental sustainability plays a significant role. Their strategies towards achieving the United Nations’ Sustainable Development Goals are comprehensive, clear, and measurable. It includes generous incentives for renewable energy investments and stringent regulations against carbon-intensive operations. This robust policy framework makes Canada an attractive destination for green tech investments and an incubator for biogas technologies.

A considerable advantage Canada has is its technological leadership in renewable energy. EverGen stands out at the forefront of renewable energy R&D, innovating and investing in RNG projects across the country to play an important role in production, storage, and distribution of RNG efficiently.

The British Columbia-based company has partnerships with jurisdictions and businesses for feedstock and output supply agreements with some of the nation’s biggest utilities, including FortisBC. FortisBC is a pioneer itself as a significant contributor to the province’s emissions reduction targets. The utility has a goal to have about 75 percent of the gas in its system being RNG or low carbon by 2050. Approached 12,000 homes and business in British Columbia are already using RNG, part of which is produced by EverGen from local organic waste.

This dovetails with the CleanBC strategy pursuant to which British Columbia is committed to a minimum requirement of 15% renewable content in the natural gas stream by 2030.

EverGen has three operations in B.C. Its Fraser Valley Biogas is an anaerobic digestion facility that utilizes local agriculture and commercial food processing waste to generate RNG and renewable fertilizer. Liquid and solid digestate matter is a byproduct of RNG production and is used as fertilizer and in other applications. Pacific Coast Renewables is an organics facility processing blended feedstock from agricultural, municipal, and commercial organic waste. Sea to Sky Soils is also an operational organics processing facility, more specifically a compost facility (feedstock from municipal and agricultural waste) operated in partnership with Lil’wat First Nation.

EverGen also has a 67% ownership of GrowTEC, an operational RNG facility in Alberta, and a 50% ownership in Project Radius in Ontario, an ambitious operating farm-scale anaerobic digester converting biodegradable waste into biogas.

Canada’s communal consciousness regarding sustainability and clean energy consumption makes it an optimal testing ground for renewable energy solutions. The country boasts one of the highest levels of education globally, with its citizens exhibiting a deep understanding and respect for the environment. This cultural attitude encourages widespread adoption of sustainable practices, creating a market for renewable energy technologies like biogas.

This harmonious blend of natural resources, proactive government policies, technological leadership, and communal consciousness has placed Canada at the forefront of the global biogas revolution. When contrasted with other countries, many lack either the necessary resources or the institutional support. For instance, while countries like Nigeria and Venezuela have enormous untapped natural resources, they lag behind due to inadequate regulatory support and sociopolitical instabilities. Countries like Singapore and the Netherlands possess strong institutional support and public awareness, but face constraints due to their limited land area and resources.

Canada’s sustainability push, particularly its focus on biogas, represents a commendable model for other countries. Its extensive natural resources, coupled with strategic government policies, leading-edge research, and a strong cultural emphasis on sustainability, have positioned Canada as a global leader in this arena. Its success in biogas utilization underscores the importance of a cohesive and well-rounded approach to sustainable development, providing valuable lessons for countries striving to make their economies greener and more sustainable.

For more information about EverGen Infrastructure, “Canada’s RNG Infrastructure Platform,” visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

Pharma, biotech, medical device, healthcare, and regulatory professionals are gathering for the 4th Aligning Drug Safety Functions & REMS Summit, taking place on August 29-30, 2023, at The Inn at Penn in Philadelphia, PA.

Set to take place in the beautiful city of Philadelphia, the conference will delve into the latest insights and address the most critical challenges surrounding drug safety and REMS (Risk Evaluation & Mitigation Strategy).

As the only event that brings together drug safety, pharmacovigilance, and risk management teams—no other conference provides as much detail and comprehensive insights into communication strategies among safety teams, prioritizing patient safety, and preparing for pharmacovigilance and REMS inspections. Attendees will walk away armed to effectively up their game and amplify patient feedback and participation in REMS programs.

Interactive and Inspirational Discussions!

With a well-rounded agenda focused on the latest advances in drug safety and REMS space, the program is designed to provide attendees with all the tools they need to develop and implement a robust global risk management plan.

Featuring interactive discussions, such as exploring the critical intersection of REMS and pharmacovigilance in shared REMS systems, discovering the power of AI to optimize REMS implementation, strategies to improve signal management and detection, fortifying compliance and quality in post-approval studies. Delve into the cutting-edge realm of patient-centricity for benefit-risk assessment and their implications for the future of healthcare.

Throughout the two-day summit, attendees will be able to connect with an outstanding lineup of expert speakers and industry leaders and learn network, and interchange ideas and innovative approaches surrounding drug safety and REMS strategies to better support patient safety.

Sign up and forge a safer and more patient-centric future at the most trusted drug safety event. Interested participants can register for this summit and secure their tickets at early-bird prices.

To learn more, please visit https://ibn.fm/otdWA.

As the Internet becomes a worldwide driver of communication and culture, enthusiasts from diverse business and entertainment backgrounds continue working toward the Internet’s evolution into a content ownership, decentralized community known as Web3.

The leadership team behind the inaugural Web3 Berlin (“W3B”) conference is determined to see it become Europe’s largest gathering of innovators in the Web3 ecosystem with gatherings on an annual basis.

The two-day event will take place at Berlin’s Estrel Congress Center (“ECC”) on June 10-11, hosting hundreds of speakers and panelists, exhibitor spaces, networking opportunities and a variety of side events such as a gamer gathering, a hackathon competition, NFT-centered parties and crypto community strategy sessions.

The Web3 evolution is ultimately designed to unleash greater utility and self-determination for users of the Internet while bringing a more level financial and technological playing field to even remote populations around the world. It’s a progression of the Internet from the original read-only content sharing model to today’s read-write content sharing, to tomorrow’s read-write-own approach to information and commerce.

The W3B conference will logically include a focus on decentralized finance (Defi), crypto universe developments as markets continue to fluctuate with some uncertainty, and the investment culture opportunities that non-fungible tokens (“NFTs”) represent as the opportunity ecosystem continues to expand.

The conference’s engaging side event activities are designed to turn the gathering into a lifestyle experience reflective of Berlin’s multicultural and history-making persona. Gamers, venture capitalists, hackers and CEOs can all be found under one roof, working toward a somewhat singular purpose as seasoned industry insiders and newcomers alike.

A VIP ticket tier is available to make the event extra productive for those seeking opportunities to network in a space amenable to relaxation over food and drinks.

Key takeaways:

• Located at one of Europe’s primary multicultural hubs
• A speaker and panel profile of 300 CEOs, financial strategists and event builders
• Forums for focusing on NFT investment, crypto community building and the decentralized finance (Defi) vision of blockchain
• Side events include a hackathon competition for developers
• A gaming space for players to connect and view the latest developments
• More than 8,000 people expected to attend
• Specialized opportunities for networking

Behind the Scenes:

The team establishing the W3B conference’s B3B infrastructure includes an energetic and diverse group of employees and advisers focused on content creation and Web3 culture. Many of them hail from backgrounds in Poland’s international gateway economy, but reflect commercial and web marketing experience built throughout Europe and Asia.

For more information about this event, please visit https://ibn.fm/51rTg.

This summer, Canada’s largest crypto, web3, and blockchain event – Blockchain Futurist Conference – returns to Rebel Entertainment and Cabana Pool Bar in Toronto, assembling more than 6,500 attendees and over 150 speakers. The unconventional venue will provide the perfect setting for a two-day one-of-a-kind crypto experience slated for August 15-16, 2023. The event will feature three stages, two floors of expo booths, crypto marketplaces, NFT galleries, blockchain bootcamps for beginners, networking events, and two developer hackathons: ETHToronto and ETHWomen.

The Main Stage will host a curated list of top speakers who will deliver presentations and industry keynotes on the future of emerging technologies and how they impact the social, economic, political, and environmental landscape of the global economy. Here, the speakers will also provide insights into industries that are being disrupted or transformed. This stage will also form the perfect setting for speakers and presenting companies to make major announcements, launch products on-stage, and showcase innovative solutions for the first time.

Three stages include panel discussions, where speakers debate technologies such as NFTs (non-fungible tokens), DAOs (Decentralized Autonomous Organizations), GameFi, the metaverse and more. The Purple Stage is geared specifically towards bootcamps and workshops, enabling beginners to learn about blockchain and allied technologies.

One consistent fact that emerges from all Blockchain Futurist Conferences is that they promise a glimpse into topics even before they become mainstream. This is thanks, in part, to the selection committee, which carefully curates the top speakers and sends specific invites for mainstage slots. This has often resulted in stellar coverage of emerging technologies. For example, during past events, attendees heard about the future of decentralized finance, NFTs, the metaverse, and artificial intelligence even before they became buzzwords. The upcoming fifth edition will be no different.

The 5th Annual Blockchain Futurist Conference will bring together world-class speakers, including:

• Charles Hoskinson, CEO and Founder of IO Global, best known for the cryptocurrency Cardano, and Tamara Haasen, President of IO Global; which is a technology and engineering company that builds blockchains and cryptocurrencies for government entities, enterprises, and academic institutions
• Michele Romanow, a resident “Dragon”, on CBC Dragons’ Den and Co-Founder and Executive Chairperson of Clearco, a company that provides equity-free capital solutions to e-commerce businesses
• Anthony Di Iorio, Founder of Andiami, Decentral, and Ethereum
• Jaime Leverton, CEO of Hut 8, an innovation-focused digital asset miner
• Ethan Buchman, Co-Founder of Cosmos, a state-of-the-art blockchain framework 
• Miko Matsumara, General Partner at gumi Cryptos Capital, a blockchain and cryptographic asset fund
• Lisa Loud, Co-Founder and CEO of FLUIEFI, a DEFI company for institutional investors
• Sascha Darius Mojtahedi, Co-Founder of Parallel, a DeFi company

Beyond the speakers, the ETHToronto and ETHWomen Hackathons will take over a month leading up to Blockchain Futurist Conference. The hackathons workshops, mentorship, mock judging and networking will take place onsite on August 15-16 at Rebel Entertainment Complex and Cabana.  This second annual Web3 hackathon, ETHToronto, is a free community event (https://ibn.fm/IqzqF). The first ever ETHWomen Hackathon is a female-focused, inclusive hackathon series that is part of the ETHToronto and Blockchain Futurist Conference (https://ibn.fm/mu6lp). Apply for free to any of the hackathons and receive free tickets to the conference.

By combining carefully curated presentations and discussions, NFT galleries, boot camps and workshops, expo booths, and networking events into a well-thought-out two-day event, Untraceable Events, the organizers of the 5th annual Blockchain Futurist Conference, ETHToronto, ETHWomen and Canada Crypto Week will indeed promise a crypto experience like no other.

To learn more, visit https://ibn.fm/mdYRG.